Professionals

David P. Dalke, Ph.D.

Of Counsel

Overview
Experience
Credentials
Insights & News

Dr. David Dalke is both a scientist and registered patent attorney with a background in immunology, genetically engineered monoclonal antibodies, and molecular biology. He has experience representing clients on matters related to life sciences including, biotechnology, nanotechnology, biochemistry, pharmaceuticals, medical devices, gene therapy, antisense technology, as well as gaming machine software, and bar code scanning technology.

Key Matters

David’s representative matters include:

Representing a global, integrated specialty pharmaceutical company in the District of Delaware in ANDA litigation relating to buccal films for treating opioid dependence.
Represented a global, integrated specialty pharmaceutical company in the District of Delaware in ANDA litigation relating to transdermal patches for treating pain.
Represented a global, integrated specialty pharmaceutical company in the District of Delaware in ANDA litigation relating to methods for manufacturing sublingual films for treating opioid dependence.
Represented a global, integrated specialty pharmaceutical company in the District of Delaware in ANDA litigation relating to a sublingual film for treating opioid dependence.
Represented a worldwide leader in generic pharmaceuticals in a patent infringement matter in the Northern District of California and the District of Massachusetts for technology relating to a biosimilar for treating rheumatoid arthritis.
Represented a pharmaceutical manufacturer in ANDA litigation in the District of Delaware relating to an injectable antibacterial drug.
Represented a global provider of integrated communications in a patent infringement matter brought by a non-practicing entity in the Northern District of Illinois for technology relating to use of barcodes to verify and authenticate mail objects.
Represented a computer peripherals supplier in a patent infringement matter pending in the District of Oregon for technology relating to covers for electronic tablets.
Represented a global pharmaceutical company in an international arbitration involving a licensing dispute over technology relating to RNA oligomers, including modified nucleosides.
Represented a world leader in the food and beverage industry in a patent infringement matter brought by a non-practicing entity in the Central District of California for technology relating to software for on-line product design. The case settled soon after a favorable Markman ruling.
Represented a leading manufacturer of slot machines in a patent infringement matter brought by a non-practicing entity in the District of Nevada for technology relating to electronic slot machines.
Represented a global medical technology company in a patent infringement matter brought by a non-practicing entity in the Southern District of California for technology relating to computer-assisted, stereotactic surgical procedures.
Represented a leading manufacturer of slot machines and casino management systems in the District of Delaware in the damages phase of a bifurcated patent litigation, after summary judgment of infringement and no invalidity was affirmed by the Federal Circuit.
Represented a leading slot machine manufacturer in a trade secret misappropriation case in Nevada state court that settled favorably after the first day of a preliminary injunction hearing.

Recent Experience

Represented TJC, LP in its Acquisition of TIDI Products Holdings, LLC, and its Subsidiaries

Capabilities

Intellectual Property

Technology, Media & Telecommunications

Key Matters

David’s representative matters include:

Representing a global, integrated specialty pharmaceutical company in the District of Delaware in ANDA litigation relating to buccal films for treating opioid dependence.
Represented a global, integrated specialty pharmaceutical company in the District of Delaware in ANDA litigation relating to transdermal patches for treating pain.
Represented a global, integrated specialty pharmaceutical company in the District of Delaware in ANDA litigation relating to methods for manufacturing sublingual films for treating opioid dependence.
Represented a global, integrated specialty pharmaceutical company in the District of Delaware in ANDA litigation relating to a sublingual film for treating opioid dependence.
Represented a worldwide leader in generic pharmaceuticals in a patent infringement matter in the Northern District of California and the District of Massachusetts for technology relating to a biosimilar for treating rheumatoid arthritis.
Represented a pharmaceutical manufacturer in ANDA litigation in the District of Delaware relating to an injectable antibacterial drug.
Represented a global provider of integrated communications in a patent infringement matter brought by a non-practicing entity in the Northern District of Illinois for technology relating to use of barcodes to verify and authenticate mail objects.
Represented a computer peripherals supplier in a patent infringement matter pending in the District of Oregon for technology relating to covers for electronic tablets.
Represented a global pharmaceutical company in an international arbitration involving a licensing dispute over technology relating to RNA oligomers, including modified nucleosides.
Represented a world leader in the food and beverage industry in a patent infringement matter brought by a non-practicing entity in the Central District of California for technology relating to software for on-line product design. The case settled soon after a favorable Markman ruling.
Represented a leading manufacturer of slot machines in a patent infringement matter brought by a non-practicing entity in the District of Nevada for technology relating to electronic slot machines.
Represented a global medical technology company in a patent infringement matter brought by a non-practicing entity in the Southern District of California for technology relating to computer-assisted, stereotactic surgical procedures.
Represented a leading manufacturer of slot machines and casino management systems in the District of Delaware in the damages phase of a bifurcated patent litigation, after summary judgment of infringement and no invalidity was affirmed by the Federal Circuit.
Represented a leading slot machine manufacturer in a trade secret misappropriation case in Nevada state court that settled favorably after the first day of a preliminary injunction hearing.

Recent Experience

Represented TJC, LP in its Acquisition of TIDI Products Holdings, LLC, and its Subsidiaries

Related Insights & News

Speeches

Co-Presenter with David Enzminger, “Developments in Intellectual Property Law – What Every General Counsel Should Know,” Association of Corporate Counsel - Southern California Chapter, Doubleheader, Los Angeles, CA (November 2013)
Co-Lecturer, “Representing the Generic Company,” Medical Products and the Law, University of Southern California, International Center for Regulatory Science (November 2013, 2014)
Speaker, “The Business of Science: Synopsis of Patent Law and Overview of the Hatch-Waxman Law,” University of California at Irvine, Paul Merage School of Business (May 2007; November 2007; February 2008)
Speaker, “Current Developments in Ethics for In-House Lawyers,” Corporate Counsel Seminar Series, Newport Beach (March 2006; October 2007)
Speaker, “How to Protect Your IP Assets and Keep Yourself in the Game: Strategic IP Planning,” Staples Center Event (April 2003)

Publications

David P. Enzminger and David P. Dalke, “Selecting a Litigation Forum From Among the District Courts and the International Trade Commission,” 2010 PLI Patent Litigation Program, at 283.
George C. Yu, David P. Dalke, and Ben Wang, “A Framework for Protecting Innovations in Personalized Medicine,” Life Sciences Law & Industry (BNA, Inc., Feb. 27, 2009).

Scientific Publications, Abstracts, and Presentations

A.E. Faassen, D.P. Dalke, M.T. Berton, W.D. Warren, and S.K. Pierce, CD40-CD40 Ligand Interactions Stimulate B Cell Antigen Processing, 25 Eur. J. Immunol. 3249-3255 (1995).
D.P. Dalke, Formation, Modulation, and Dissociation of Naturally Processed Antigen-MHC Class II Complexes in Murine B Lymphocytes (1994) (Ph.D. dissertation, Northwestern University).
Y. Qiu, X. Xu, A. Wandinger-Ness, D.P. Dalke, and S.K. Pierce, Separation of Subcellular Compartments Containing Distinct Functional Forms of MHC Class II, 125 J. Cell Biol. 595-605 (1994).
S.K. Pierce, A.E. Faassen, Y. Qiu, X. Xu, P. Schafer, and D.P. Dalke, Regulation of Antigen Processing and Presentation in B Lymphocytes, in Regulation of Antigen Processing (R. Humphrey and S.K. Pierce, editors, Academic Press, 1993).
E.W. Marsh, D.P. Dalke, and S.K. Pierce, Biochemical Evidence for the Rapid Assembly and Disassembly of Processed Antigen-MHC Class II Complexes in Acidic Vesicles of B Cells, 175 J. Experimental Med. 425-436 (1992).
D.P. Dalke, and S.K. Pierce, The Disassembly of Processed Antigen-Class II Complexes, FASEB Annual Meeting at Anaheim, California (1992).
D.P. Dalke, Antigen Processing and Presentation in B Lymphocytes, Biology Department Seminar at St. Mary’s College of Minnesota, Winona, Minnesota (1992).
D.P. Dalke, E.W. Marsh, and S.K. Pierce, Both Assembly and Disassembly of Processed Antigen-MHC Class II Complexes Require Acidic Vesicle Function, American Society for Cell Biology Annual Meeting at Boston, Massachusetts (1991).